Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;4(1):76-83.
doi: 10.4103/0975-7406.92743.

Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat

M Teixeira  1 , P Rodrigues-Santos, P Garrido, E Costa, B Parada, J Sereno, R Alves, L Belo, F Teixeira, A Santos-Silva, F Reis
Affiliations

Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat

M Teixeira et al. J Pharm Bioallied Sci. 2012 Jan.

Abstract

Objective: Recombinant human erythropoietin (rhEPO) therapy under circumstances of moderate chronic renal failure (CRF), with yet lower kidney and heart lesion, may have a protective cardiac effect beyond the correction of anemia, whose mechanism deserves better elucidation, namely by clarifying the impact on gene expression profile of markers of apoptosis, inflammation, proliferation, angiogenesis, and lesion/stress in the heart.

Materials and methods: Four groups of rats were studied over a period of 15 weeks (n=7 each): control-without surgery and without drug treatment; rhEPO-treated with 50 IU/kg/week of rhEPO-beta; CRF-submitted to partial nephrectomy (3/4); CRF + rhEPO-CRF with rhEPO treatment after the 3rd week of surgery. The heart was collected in order to evaluate the gene expression, by real-time qPCR, of markers of apoptotic machinery, inflammation/immunology, proliferation/angiogenesis, and lesion/stress.

Results: The main findings obtained were (a) CRF rats have demonstrated overexpression of EPO-R in the heart without changes on EPO expression, together with overexpression of Bax/Bcl2 ratio, PCNA, and IL-2; (b) rhEPO therapy on the heart of the rats with CRF induced by partial 3/4 nephrectomy promoted nonhematopoietic protection, demonstrated by the apoptosis prevention, viewed by the Bax/Bcl2 balance, by the promotion of proliferation, due to PCNA increment, and by the immunomodulatory action, expressed by a trend to prevent the IL-2 increment.

Conclusion: In this model of moderate CRF, rhEPO treatment showed important cardiac nonhematopoietic effects, expressed mainly by the antiapoptotic and the proproliferative action, suggesting that early rhEPO therapy in moderate stages of CRF might have further therapeutic benefits.

Keywords: Apoptosis; cardiovascular protection; gene expression; moderate chronic renal failure; proliferation/angiogenesis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Heart mRNA erythropoietin (a) and erythropoietin receptor (b) gene expression for the groups under study, at the final time. Results are means ± SEM of arbitrary units (7 rats/group): aP < 0.05 and aaP < 0.01 vs the control group.
Figure 2
Figure 2
Heart mRNA Bax/Bcl2 ratio (a), PCNA (b), and IL-2 (c) gene expression for the groups under study, at the final time. Results are means ± SEM of arbitrary units (7 rats/group): aP < 0.05, aaP < 0.01, and aaaP < 0.001 vs the control group; bP < 0.05 and bbP < 0.01 vs the CRF group
See this image and copyright information in PMC

References

    1. Deicher R, Hörl WH. Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2003;12:139–43. - PubMed
    1. Miranda Sde P, Macedo RN, Silva Júnior GB, Daher Ede F. Cardio-renal syndrome: Pathophysiology and treatment. Rev Assoc Med Bras. 2009;55:89–94. - PubMed
    1. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular disease. Eur Heart J. 2004;25:285–91. - PubMed
    1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anaemia on cardiomyopathy morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61. - PubMed
    1. Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity – the experience of the Lombardy dialysis Registry. Nephrol Dial Transplant. 1998;13:1642–4. - PubMed